OCT 09, 2019 07:30 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Keynote Presentation: Pairing protein profiling with drug screens uncovers an effective therapy against high risk leukemia

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Assistant Adjunct Professor in the Department of Pediatrics/Hematology at UCSF
    Biography
      Ernesto Diaz-Flores, PhD, is an Assistant Adjunct Professor in the Department of Pediatrics/Hematology at UCSF. He is an experienced biochemist with a focus on identifying novel therapeutics for high-risk childhood leukemia. Dr. Diaz-Flores obtained his BsC in Biochemistry at the Universidad Complutense (Madrid) and his PhD in molecular biology for his studies of lymphocyte activation at the Universidad Autonoma (Madrid). He came to UCSF for his postdoctoral studies first under the supervision of Dr Kevin Shannon, studying murine models of Kras leukemia and then pursuing a second postdoctoral fellowship in Dr. Mignon Loh's laboratory. Dr Diaz-Flores specializes in identifying novel therapies for children with hypodiploid leukemia. His work combines the study of dysregulated signaling networks, transcriptomics analysis and drug assays. He further validates drugs with therapeutic potential running in vivo preclinical trials using patient derived xenografted models. His latest work has informed a clinical trial for patients with high-risk leukemia

    Abstract:

    Acute lymphoblastic leukemia is the most common cancer in children and adolescents. While current treatments have resulted in 85-90% cure, the remaining 10-15% cases represent the leading causes of childhood cancer mortality. This is largely due to specific leukemia subtypes being resistant to treatment. One of these subtypes is hypodiploid B cell leukemia characterized by multiple chromosomal losses. For these patients, treatment options remain limited, and their prognosis is dim.

    Learning Objectives:
    1. how to integrate genomics and proteomics profiling with drug screens to identify potential therapeutic targets
    2. how to move from in vitro to in vivo preclinical studies to inform new clinical trials.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    JUL 31, 2019 09:00 AM PDT
    C.E. CREDITS
    JUL 31, 2019 09:00 AM PDT
    DATE: July 31, 2019TIME: 9:00am PT, 12:00pm ET The choroid plexus, which makes up the blood-cerebrospinal fluid barrier in the central nervous system (CNS), lines the ventricle...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    AUG 15, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 15, 2019 09:00 AM PDT
    DATE: August 15, 2019TIME: 9:00am PDT, 12:00pm EDT Radiation therapy is a critical tool for the treatment of brain tumors, however, exposure to high doses of ionizing radiation...
    Loading Comments...
    Show Resources
    Event Countdown
    • 0 Days
    • 0 Hours
    • 0 Minutes
    • 0 Seconds